The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...
Researchers from Cytovia Therapeutics Inc. have presented preclinical data for the novel natural killer (NK) cell engager antibody CYT-338, which was designed using the proprietary FLEX-NKTM platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback